Dr. Michael Beckert Steps Down as EVP and CMO of LifeCycle Pharma

Company Announcement no. 32/2008

To: OMX Nordic Exchange Copenhagen	                     Hørsholm, Denmark,
September 18, 2008 


Dr. Michael Beckert Steps Down as EVP and CMO of LifeCycle Pharma 
Effective December 31, 2008. 
Dr. Karin Hamberg Will Assume Responsibility of 
Clinical, Regulatory & Medical Affairs

LifeCycle Pharma A/S (OMX:LCP) announced today that Dr. Michael Beckert has
decided to resign as EVP and CMO of LifeCycle Pharma in order to pursue other
opportunities outside LCP effective December 31, 2008. Dr. Karin Hamberg, who
is currently EVP of Drug Delivery Research and Alliance & Project Management,
will assume responsibility for Clinical, Regulatory, and Medical Affairs
undertaking Dr. Beckert's responsibilities. Dr. Hamberg will be registered with
the Danish Commerce and Companies Agency as member of the management board. 
 “We regret Dr. Beckert's decision to leave LifeCycle Pharma. At the same time,
I would like to thank Dr. Beckert for his significant contributions to the
Company. Under his tenure, LifeCycle Pharma has efficiently built an
international clinical, regulatory and medical group in Denmark and the U.S.
for the upcoming Phase III programs,” says Dr. Claus Braestrup. 
“Under Dr. Michael Beckert's tenure, LifeCycle Pharma achieved approval of its
first product, Fenoglide, by the US Food and Drug Administration (FDA) in 2007,
and subsequently, it was launched in the US in February 2008 via our partner,
Sciele Pharma. Furthermore, Dr. Beckert brought LifeCycle Pharma's two lead
candidates, LCP-Tacro, a once-daily dosage formulation of tacrolimus for
immunosuppression treatment, and LCP-AtorFen,  a combination product of
atorvastatin and fenofibrate for lipid-lowering treatment, through Phase II,
including preparation for Phase III which is expected to be initiated before
the end of 2008,” Dr. Braestrup elaborates. 
“It was a very difficult decision for me,” says Michael Beckert, “however,
after more than 4 years, it is time to think ahead and very personal reasons
were leading to the decision to leave LifeCycle Pharma as Chief Medical
Officer. I am proud of what we have accomplished during this period, and I am
looking forward to supporting LCP in the future in the role as a Consultant.” 
Dr. Hamberg who serves as EVP currently responsible for Drug Delivery Research
and Alliance & Project Management will assume responsibility of Clinical,
Regulatory, and Medical Affairs. 

Prior to joining LCP, Dr. Hamberg served as Vice President of Development at
LEO Pharma A/S, where she held various management positions within Development
and R&D Project Management for the past 15 years. Mrs. Hamberg obtained her
Medical Degree from University of Copenhagen and holds several diplomas
including a Swiss Diploma in Pharmaceutical Medicine. 

 “I am very pleased to announce that Karin will take responsibility of
clinical, regulatory and medical affairs” said Dr. Claus Braestrup. “We are in
an exciting stage of development, and we are very much looking forward to
utilizing Karin's knowledge and experience in collaboration with those of our
other experienced executive team members within the company.” 

For more information, please contact:

LifeCycle Pharma A/S	
		
Dr. Claus Braestrup			Hans Christian Teisen
Chairman of the Board			EVP & CFO
Phone: +45 4050 8050 			Phone: +45 2030 6985

About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). For further information, please visit www.lcpharma.com.